Navigation Links
PTC124 Featured at Third Annual Congress of Myology
Date:5/30/2008

- PTC Announces Initiation of Additional Phase 2b Clinical Trial Sites in

Europe -

SOUTH PLAINFIELD, N.J., May 30 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that PTC124, the company's orally delivered investigational new drug for the treatment of genetic disorders due to nonsense mutations, was featured in a symposium at Myology 2008, the Third Annual Congress of Myology, on Friday, May 30 in Marseilles. The Congress serves as the annual meeting of The Association Francaise contre les Myopathies (French Muscular Dystrophy Association) and focuses on research, therapies and clinical trials for various forms of muscular dystrophy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO)

PTC124 is being studied in Duchenne muscular dystrophy (DMD), a progressive muscle disorder in which patients lack dystrophin, a protein that is critical to the structural stability of muscle fibers. PTC recently launched a global, registration-directed Phase 2b trial in DMD and Becker muscular dystrophy (BMD) to evaluate the efficacy of PTC124 as measured by improvements in the walking ability of patients with this progressive genetic disease.

Data from the previous Phase 2a study were presented and discussed by a panel of leading physicians and researchers, including: Dr. Thomas Voit, M.D., Medical and Scientific Director of the Myology Institute and Dr. Richard Finkel, M.D., Director of the Neuromuscular Program, Children's Hospital of Philadelphia, PA.

"PTC124 represents a promising new therapy for DMD/BMD, as there are currently no available treatments that address the underlying cause of this disease," stated Dr. Voit. "The Phase 2b PTC124 clinical trial sets a gold standard for future clinical trials in muscular dystrophies. I am delighted to be part of these groundbreaking studies."

Presenters at
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
2. Boston Scientifics SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R)
3. Michael V. Novinski, Emisphere President/CEO Featured in the Wall Street Transcript
4. Featured Stocks on Todays Edition of WallSt.nets 3-Minute Press Show: NPHC, PECD, PNRR
5. Featured Stocks on Todays Edition of WallSt.nets 3-Minute Press Show: BFNH, BKYI, RBCL
6. NeoStem Featured in WCBS-TV Health Watch Segment on Adult Stem Cells
7. CT Laser Mammography Technology to be Featured at European Congress of Radiology
8. Cord Blood America Subsidiary Featured at NASCAR Sprint Cup Series Race
9. CT Laser Mammography Technology to be Featured at Interdisciplinary Breast Cancer Conference
10. CardioDynamics BioZ(R) ICG Technology Featured in American College of Cardiology (ACC) Audio Series
11. Marteks lifesDHA(TM) Now Featured in Two New Flavors of Rachels(R) Wickedly Delicious Yogurt from WhiteWave Foods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... pace of growing computing power could be sustained for ... from the UK,s National Physical Laboratory (NPL) that is ... observed that the density of transistors on an integrated ... time to achieve this, but experts believed that when ...
... OMAHA, Neb., Dec. 9 Transgenomic, Inc.,(OTC Bulletin ... been,awarded an accreditation by the Commission on Laboratory ... on the results of a recent,on-site inspection. Transgenomic ... laboratories nationwide. , Craig Tuttle, CEO ...
... Kingdom and MONTREAL, Dec. 9 /PRNewswire-FirstCall/ - ProMetic ... U.K.-based subsidiary, ProMetic BioSciences Ltd ("PBL"), has signed ... world-leading European Biopharmaceutical company estimated to be worth ... years, with first shipment delivery starting this quarter. ...
Cached Biology Technology:Transgenomic Receives Accreditation From College of American Pathologists 2Transgenomic Receives Accreditation From College of American Pathologists 3ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company 2ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company 3
(Date:4/24/2014)... State University and the University of North Carolina at ... could help identify arterial plaque that is at high ... stroke. , At issue is the plaque that builds ... plaque are deemed "vulnerable," meaning that they are more ... heart attack or stroke. , "Existing state-of-the-art technologies are ...
(Date:4/24/2014)... RICHLAND, Wash. A common plant puts out a welcome ... the mat,s molecular mix. , The study published this week ... reveals new targets during the battle between microbe and ... team showed that the humble and oft-studied plant Arabidopsis ... from a pathogen. It,s as if a hostile army were ...
(Date:4/23/2014)... German . Man ... difference between sexes depends on one single element of the genome: ... two sexual chromosomes are X and Y, whereas women have two ... morphological and physiological differences between males and females. , But this ... the X and Y were identical, until the Y started to ...
Breaking Biology News(10 mins):New ultrasound device may add in detecting risk for heart attack, stroke 2How a plant beckons the bacteria that will do it harm 2How a plant beckons the bacteria that will do it harm 3Male or female? 2Male or female? 3
... the diet for Thanksgiving? Turkey with all the fixings ... their goals, according to a new Cornell University review ... willpower every day. "We,re slaves to our environment," ... psychology at Cornell, who co-authored the article with graduate ...
... WASHINGTON, Nov. 16, 2011 A new episode ... Challenges/Chemistry Solutions" podcast series spins a real-life tale ... major barrier to the use of gene therapy in ... largest scientific society explains in non-technical language that gene ...
... DURHAM, New Hampshire, November 16, 2011 A study ... Thursday, Nov. 17, concludes that forests influence temperature, and ... Hollinger, a plant physiologist with the U.S. Forest Service,s ... Xuhui Lee, a professor of meteorology at the Yale ...
Cached Biology News:New American Chemical Society podcast: Genetically-engineered spider silk for gene therapy 2Forests cooler or warmer than open areas depending on latitude, study finds 2